Addressing the Human Experience of Chronic Kidney Disease: A Call to Transform Kidney Care.

Autor: Correa-Rotter R; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. correarotter@gmail.com., Chadban SJ; Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia., Christen L; Global Patient Advocacy, BioPharmaceuticals Medical, AstraZeneca, Baar, Switzerland., Damron KC; Patient Engagement Director, National Kidney Foundation, New York, NY, USA., Hamusankwa L; Patient Author, London, UK., Jarvis S; Patient.Info, London, UK., Pentakota S; Global Medical Affairs Leader, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Robles M; Patient Author, Mexico City, Mexico., Stevens P; Patient Engagement, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Wanner C; Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, University Hospital of Würzburg, Würzburg, Germany.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2024 Dec 02. Date of Electronic Publication: 2024 Dec 02.
DOI: 10.1007/s12325-024-03048-9
Abstrakt: Chronic kidney disease (CKD), a long-term condition in which kidney function declines over time, is a growing global healthcare concern. CKD can have a major impact on the quality of life of patients and their caregivers. Recent research by the International Society of Nephrology highlights that current treatment strategies and policies do not fully address patients' needs. This commentary provides patient insights into the real-life concerns of those who are living with CKD, with main concerns focusing on relationships and support, work and finances, and awareness, prevention, and intervention. Strong support networks are essential for patients and caregivers, but the burden of CKD can make it difficult to maintain personal connections. Limiting disease progression and providing mental health support can help patients and caregivers to maintain their relationships. Work or education can be challenging to manage with CKD; however, employers and educational institutions can create supportive environments that meet the diverse needs of people with CKD. Although delaying disease progression can preserve patient quality of life, people are often unaware of their disease prior to diagnosis, the severity of their CKD, and the risk factors for progression. This presents an opportunity to involve patients in their care by improving education about the benefits of maintaining kidney health. Early identification and holistic intervention could slow disease progression and protect the well-being of patients with CKD and their caregivers. This commentary brings together the diverse perspectives of patients and patient advocacy groups, as well as primary care and specialist healthcare professionals, to advocate for a transformation of CKD management that encourages patient self-care and that prioritizes timely intervention.A patient perspective video and a graphical abstract are available with this article. Addressing the Human Experience of Chronic Kidney Disease: A Call to Transform Kidney Care. Watch Lweendo Hamusankwa discuss his experience of living with chronic kidney disease, from how it impacted his family life to the importance of support networks and patient-facing information. Lweendo advocates for patients to be educated on CKD progression, treatment options, and lifestyle interventions to encourage people to manage their own health and well-being.
Competing Interests: Declarations. Conflict of Interest: Ricardo Correa-Rotter has provided consultancy and received fees from AbbVie, AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim; has lectured for Amgen, Janssen, AstraZeneca, and Boehringer Ingelheim; and has received research support from GlaxoSmithKline, Novo Nordisk, and AstraZeneca. Steven J. Chadban has received payment or honoraria from AstraZeneca, Bayer, and Boehringer Ingelheim for speaker fees and advisory board participation. Laura Christen, Surendra Pentakota, and Petrina Stevens are employees of AstraZeneca. Surendra Pentakota and Petrina Stevens hold stock options. Kelli Collins Damron is an employee of the National Kidney Foundation. Lweendo Hamusankwa and Marisol Robles have no conflicts of interest to disclose. Sarah Jarvis is a Chief Medical Advisor for IBEX Innovations, locum general practitioner, medical broadcaster and former clinical consultant for Patient.info. Sarah Jarvis has received payment or honoraria from AstraZeneca, Boehringer Ingelheim, Lilly, Merck, and Novartis for speaker fees and advisory board participation. Christoph Wanner has provided consultancy to AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, and Merck. Ethical Approval: This article is based on author experience and previously published research, and does not contain any new studies with human participants or animals performed by any of the authors. Patient Involvement: Patient authors shared their experience of living with CKD, which informed the key areas of concern (Relationships and Support; Work and Finances; Awareness, Intervention and Prevention of Disease Progression), and also contributed to the planning and development of this commentary.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: